Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-α therapy

Authors

  • Jin-Ying Lu,

    1. Department of Laboratory Medicine,
    2. Division of Endocrinology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan,
    3. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan,
    Search for more papers by this author
  • Lee-Ming Chuang,

    1. Division of Endocrinology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan,
    Search for more papers by this author
  • Wei-Shiung Yang,

    1. Division of Endocrinology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan,
    2. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan,
    Search for more papers by this author
  • Tong-Yuan Tai,

    1. Division of Gerontology Research, National Health Research Institutes, Taipei, Taiwan,
    Search for more papers by this author
  • Ming-Yang Lai,

    1. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan,
    2. Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Search for more papers by this author
  • Pei-Jer Chen,

    1. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan,
    2. Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Search for more papers by this author
  • Jia-Horng Kao,

    1. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan,
    2. Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Search for more papers by this author
  • Cha-Ze Lee,

    1. Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Search for more papers by this author
  • Hsuan-Shu Lee

    1. Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Search for more papers by this author

Prof. Tong-Yuan Tai, Division of Gerontology Research, National Health Research Institutes, 2F, 109, Min-Chuan East Road, Sec 6, Taipei 114, Taiwan.
Tel: +886-2-2653-4401 ext. 8601
Fax: +886-2-26513723
e-mail: tytai@nhri.org.tw

Abstract

Abstract: Aims: The study was designed to survey the change of adiponectin levels before and after interferon-α (IFN-α) therapy in patients with chronic hepatitis B and C infections.

Methods: Twenty-one biopsy-proved patients with chronic hepatitis B (10 cases) and hepatitis C (11 cases) were given IFN-α for a total of 24 weeks. Fasting plasma glucose, insulin and adiponectin levels were obtained before and 12 weeks after completion of IFN-α therapy. Insulin suppression test was conducted before and within 1 week after IFN-α therapy.

Results: The change of adiponectin levels differed significantly between responders (eight cases) and non-responders (13 cases) to IFN-α treatment (−4.8±2.2 vs. 0.5±1.0 μg/ml, P=0.03). After adjusting for age, gender and change in body mass index, the study found the change of adiponectin levels still significantly related to the response to IFN-α (P=0.04). When hepatitis B virus (HBV) and hepatitis C virus (HCV)-infected patients were separately analyzed, the adiponectin levels reported a trend to decrease in HCV responders (11.9±3.2 vs. 10.8±3.0 μg/ml, P=0.02, n=4) and HBV responders (17.7±4.1 vs. 9.2±1.0 μg/ml, P=0.10, n=4). In addition, a significant decrease of steady-state plasma glucose in insulin suppression test was noted in responders (13.6±1.8–11.7±1.2 mmol/l, P=0.03), but not in non-responders (12.3±1.1–11.0±1.0 mmol/l, P=0.20), after IFN-α therapy.

Conclusions: IFN-α resulted in a decrease of serum adiponectin levels but an improvement of insulin resistance in responders to the treatment. The result contradicts previous concept of the relationship between insulin resistance and adiponectin levels. Whether and how the augmented immune response, which was supposed to result from the disappearance or the profound down-regulation of the virus or viral antigens in responders to IFN-α treatment, contributes to the lowering of adiponectin levels needs to be further investigated.

Ancillary